2023年3月22日

新闻分享这篇文章分享这篇文章提供的温哥华公元前3月22日2023 /价值/ - CuePath创新药物依从性解决方案提供者的家庭医疗保健市场,今天宣布,它已被选为药物治疗依从性监测系统临床试验由中心医院因为学校蒙特利尔研究中心(CRCHUM)。这将是第一个临床试验在加拿大使用Cuepath自动化药物依从性监测的研究协议。临床试验是由加拿大卫生研究院资助的研究,定于2023年6月开始。临床试验将研究药物治疗和心理干预,单独和组合,对于那些生活在甲基苯丙胺使用障碍。临床试验通常依赖于参与者自我报告或每日摄入在药房记录服药情况。CuePath带来其自动服药情况监测和分析临床试验,所以研究人员可以准确地监测和收集详细的数据在药物摄入,提高病人安全,允许更好的证据整体治疗依从性。CuePath首席执行官肯•比亚乔说,“这将是第一个临床试验在加拿大使用CuePath自动化药物依从性监测。”Piaggio continued, "We expect this to be the first of many more clinical trials in North America that employ our innovation technology. We are excited to work with CRCHUM and its research partners to improve the healthcare of Canadians." About Centre Hospitalier de l'Université de Montréal Research Centre The Centre Hospitalier de l'Universite de Montreal Research Centre is one of North America's leading hospital research centres. It strives to improve the health of adults through a continuum of research spanning disciplines such a basic science, clinical research and population health. More than 2,150 people work at CRCHUM, including nearly 500 researchers and 650 students and postdoctoral fellows. www.crchum.com About CuePath CuePath Innovation™ is a healthcare technology company focused on improving medication adherence of adults with chronic conditions. Its mission is to bring peace of mind to caregivers by improving the quality of life of its customers. CuePath couples its Medication Adherence as a Service (MAaaS) platform with its outcomes-based virtual care service to resolve patient non-adherence. It partners with leading home care agencies and pharmacies to deliver its innovative and effective subscription service.